Netherlands-based SurgVision is developing a real-time fluorescence image guided surgery platform which combines targeted imaging agent and a tumor visualization device designed for use during oncology surgical procedures, Bracco said.
“With the acquisition of SurgVision, one of the most advanced companies in a very promising field, we intend to address a relevant, unmet medical need for oncology patients who have to undergo tumor removal surgery. SurgVision platform expands our imaging solutions for healthcare professionals in oncology and reinforces our long-lasting commitment to patient care,” Bracco CEO Fulvio Bracco said in a prepared statement.
“The investment in Surgvision provides Bracco Imaging with key competencies and technologies strategically adjacent to our core business and, at the same time, will accelerate the development of the projects currently in scope of our research and development efforts,” Bracco chief strategy officer Micol Fornaroli said in a press release.
Bracco said it expects SurgVision’s platform to provide “significant improvements” against current competing modalities and products due to its advanced optical camera and new imaging agent.
“The acquisition of SurgVision by Bracco is a vote of confidence for the field of fluorescence image- guided surgery and for the achievements so far by the SurgVision team. The expertise and commitment from Bracco will allow SurgVision to continue developing a solution that delivers on the potential of important clinical benefits for patients,” SurgVision CEO Ton van den Hoven said in prepared remarks.
In January, the Bracco Diagnostics subsidiary said it won FDA approval for its Lumason microsphere contrast agent to be used in ultrasonography of the urinary tract in pediatric patients with suspected or known vesicoureteral reflux.